Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.
Michelle Sharp, MD, MHS, shared insights into the complexities of sarcoidosis, describing how she evaluates, diagnoses and treats patients.
Dr. Feely discusses his previous work with the College, his current work as a practicing rheumatologist and how he will lead continued advances on the insurance front.
Research & patients reap benefits when patients with rheumatic conditions get involved in patient-facing organizations & in clinical research planning.
We recently learned that Bruce McNeil Milburn, MD (70), passed away Dec. 27, 2024, from complications of amyotrophic lateral sclerosis (ALS). He was diagnosed with ALS just a year ago. Dr. Milburn was a practicing rheumatologist in Brevard County, Fla., for more than 30 years. Born on March 23, 1954, Dr. Milburn dedicated his life…
As new chair of the Committee on Education, Marcy Bolster, MD, wants to foster opportunities for rheumatologists and other specialists to connect through education.
As of Jan. 1, rheumatology practices face significant changes in coding and reimbursement for telemedicine services, including new and deleted billing codes, updated Medicare policies and looming expiration of pandemic-related flexibilities.
This spring, the ACR will be distributing a survey to collect data about academic and community practice productivity, finances, staffing, technology and more. It’s critical members report the most accurate data possible to help the ACR address members’ needs, and enable rheumatologists and practices maintain economic viability.
In 2024, key federal healthcare regulations and policy developments—related to health insurance, privacy protections, reimbursement, biosimilar use and more—shaped the landscape of the practice of rheumatology in several important ways.